WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NURO),
an innovative health-care company that develops wearable medical
technology and point-of-care tests that help patients and physicians
better manage chronic pain, nerve diseases, and sleep disorders, today
reported that over 200,000 Medicare Advantage members have been assessed
for diabetic neuropathy with the DPNCheck device.
DPNCheck provides Medicare Advantage organizations with a clinically
superior method of detecting diabetic neuropathy compared to the
traditional monofilament test that's typically used in the primary care
setting. This quantitative test measures standard nerve conduction
parameters providing physicians with objective data that helps determine
if the individual has diabetic neuropathy.
"DPNCheck represents a significant clinical advance for Medicare
Advantage organizations," said Michael MacDonald, NeuroMetrix Senior VP
of Commercial Operations. "These organizations depend on reliable
diagnostic data to accurately risk assess their members and then
proactively manage those with neuropathy to prevent debilitating and
costly complications such as foot ulcers and falls."
About DPNCheck
DPNCheck is a quantitative nerve conduction test that is used by
physicians and health care professionals to evaluate systemic
neuropathies such as diabetic peripheral neuropathy, or DPN. It is
designed to be used at the point-of-care to objectively detect, stage,
and monitor DPN. The device measures nerve conduction velocity and
response amplitude of the sural nerve, a nerve in the lower leg and
ankle. These parameters are recognized as sensitive and specific
biomarkers of DPN.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150827005194/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
